New German Law Stabilizes Statutory Health Insurance Contribution Rates

Germany's GKV-Beitragssatzstabilisierungsgesetz, a new law aimed at stabilizing contribution rates for the statutory health insurance system (GKV), has been enacted. The legislation, published in the Federal Law Gazette on July 29, 2026, will come into force in significant parts on July 30, 2026, with further provisions taking effect later.

The law mandates a fixed, indefinite manufacturer rebate of 8.5%, increasing the total rebate to 15.5%. Exceptions are provided for biosimilars, reference biologics, and clinical trials significantly conducted in Germany. A separate vaccine rebate will be raised to 9%. These measures, intended to manage costs within the GKV, will largely apply to drugs dispensed from January 1, 2027.

Further adjustments include an increase in the rebate factor for price-volume agreements, raising it from 1% to 1.5% for revenues exceeding €100 million, effective July 30, 2026. Additionally, rebate contracts for patented drugs with therapeutically comparable effects will be piloted for five substance groups until December 31, 2030. The drug price moratorium will also be extended to the end of 2030.

The law also excludes homeopathic and anthroposophic medicines and services from GKV coverage starting January 1, 2027. However, eligible patients with severe conditions will gain access to standardized cannabis extracts, with provisions for a six-month therapeutic trial starting July 30, 2026.

These legislative changes are designed to ensure the financial stability of the statutory health insurance system while impacting pharmaceutical pricing strategies and patient access to certain therapies within Germany.